Lu AA24530 for the treatment of mood and anxiety disorders enters into clinical phase II
Lu AA24530, discovered by Lundbeck, belongs to a new chemical class and represents an approach that is different to currently marketed antidepressants. Lu AA24530 is being jointly developed by Lundbeck and Takeda and is the second most advanced compound in the collaboration on a new class of compounds to treat mood and anxiety disorders.
In September 2007, Lundbeck and Takeda formed an alliance to develop and commercialize a portfolio of novel compounds in the US and Japan for the treatment of mood and anxiety disorders, including Lu AA24530 and Lu AA21004, which is in a more advanced clinical development stage.
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.